NCT05462587View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II

PHASE3RecruitingINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Leukocyte Adhesion Deficiency

Interventions

DRUG

AVTX-803 (L-Fucose)

L-fucose crystalline powder

Trial Locations (1)

55905

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

AUG Therapeutics

All Listed Sponsors

lead

AUG Therapeutics

INDUSTRY